Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Carhart-Harris, who is chair of TYP’s scientific advisory board, and Mediano, of the Imperial College London, will work with Tryptamine Therapeutics’ (ASX:TYP) to develop a proprietary EEG-based ...
The open-label trial will be run in partnership with Swinburne University and plans to test Tryptamine’s IV psilocin therapy TRP-8803, with supportive psychotherapy. Watch the video to hear the ...
Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...
A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback